| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Fungal cell wall/membrane; mitochondrial apoptotic pathway.
|
|---|---|
| ln Vitro |
Medioresinol exhibits antifungal activity against Candida albicans by inducing intracellular reactive oxygen species (ROS) accumulation and mitochondrial-mediated apoptosis. It has antibacterial and bactericidal activities. The compound synergizes with antibiotics to enhance antimicrobial and antibiofilm effects. It also has leishmanicidal activity.
|
| ln Vivo |
Medioresinol has been reported to have in vivo efficacy in models of fungal infection. The compound may reduce the risk of cardiovascular disease. It enhances the efficacy of antibiotics through its antimicrobial and antibiofilm properties. Further in vivo studies would be needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro antifungal assays use Candida albicans cultures grown in appropriate medium. Medioresinol is added at concentrations ranging from 1-100 µg/mL. Minimum inhibitory concentration (MIC) is determined by broth microdilution according to CLSI guidelines. ROS accumulation is measured using fluorescent probes (e.g., DCFH-DA). Mitochondrial membrane potential is assessed using JC-1 dye. Apoptosis is confirmed by Annexin V/PI staining and flow cytometry.
|
| Cell Assay |
In vitro cellular assays are performed using Candida albicans or bacterial cultures. Cells are treated with Medioresinol at concentrations ranging from 1-100 µg/mL for 4-24 hours. Cell viability is measured by CFU counting or using resazurin-based assays. ROS levels are measured by fluorescence. Mitochondrial dysfunction is assessed by measuring ATP levels and cytochrome c release. Antibiofilm activity is evaluated using crystal violet staining of biofilm biomass.
|
| Animal Protocol |
In vivo efficacy is evaluated in mouse models of candidiasis. Mice are infected with Candida albicans intravenously or orally. Medioresinol is administered orally or intraperitoneally at doses ranging from 10-100 mg/kg. Survival, fungal burden in organs (kidney, liver, spleen), and histopathological analysis are assessed. For cardiovascular studies, appropriate models of atherosclerosis or dyslipidemia would be used.
|
| ADME/Pharmacokinetics |
Medioresinol has a molecular weight of 388.41 g/mol and molecular formula C21H24O7. CAS number: 40957-99-1. Purity ≥98%. Appearance: White to off-white solid powder. Store as a powder at -20°C. Soluble in DMSO. LogP: 1.12. Density: 1.3±0.1 g/cm3.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for Medioresinol. As a research compound, it is not intended for human use and has not undergone formal toxicological evaluation. Standard preclinical safety assessments would include cytotoxicity profiling in mammalian cell lines, hERG channel inhibition for cardiac safety, and CYP450 enzyme inhibition for drug-drug interaction potential. The compound is for research use only.
|
| References |
|
| Additional Infomation |
(-)-medioresinol is a lignan with the structure tetrahydro-1H,3H-furano[3,4-c]furan, substituted at position 1 with 4-hydroxy-3,5-dimethoxyphenyl and at position 4 with 4-hydroxy-3-methoxyphenyl. It has been isolated from the stems of Sinocalamus affinis. It is a plant metabolite. It is a lignan, dimethoxyphenyl, furan, and polyphenol compound. Medioresinol has also been reported in Gnetum montanum, Aralia bipinnata, and several other organisms with relevant data.
Medioresinol is a research-grade furofuran-type lignan with antimicrobial and antifungal activities. It is not approved for clinical use. Also known as (+)-Medioresinol. It has been isolated from the stems of Sinocalamus affinis and other plants. It is a plant metabolite. The compound is supplied as a powder with high purity and should be stored desiccated at -20°C. |
| Molecular Formula |
C21H24O7
|
|---|---|
| Molecular Weight |
388.41106
|
| Exact Mass |
388.152
|
| CAS # |
40957-99-1
|
| PubChem CID |
181681
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
575.7±50.0 °C at 760 mmHg
|
| Flash Point |
302.0±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.587
|
| LogP |
1.12
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=CC(=CC(=C1O)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O)OC
|
| InChi Key |
VJOBNGRIBLNUKN-BMHXQBNDSA-N
|
| InChi Code |
InChI=1S/C21H24O7/c1-24-16-6-11(4-5-15(16)22)20-13-9-28-21(14(13)10-27-20)12-7-17(25-2)19(23)18(8-12)26-3/h4-8,13-14,20-23H,9-10H2,1-3H3/t13-,14-,20+,21+/m0/s1
|
| Chemical Name |
4-[(3S,3aR,6S,6aR)-3-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~128.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5746 mL | 12.8730 mL | 25.7460 mL | |
| 5 mM | 0.5149 mL | 2.5746 mL | 5.1492 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
